Author Index to Volume 5 (1988)

Aasen, A. J., 236
Abbiati, G., 430
Achari, R., 190
Addicks, W. J., 377
Amidon, G. L., 193, 592, 645, 651
Anderson, B. D., 140, 482, 566
Anderson, L. D., 165
Ando, H. Y., 729
Ascher, N. L., 781
Audus, K. L., 369
Aunet, D. A., 514
Aungst, B. J., 44, 615
Awazu, S., 341, 786

Babay, D., 178
Barth, J., 509
Bauer, J. F., 664
Becker, A. R., 523, 528
Behling, A. R., 501
Benita, S., 178
Berg, M. J., 183
Berner, B., 660
Berninger, R. W., 325
Berry, B. W., 123
Bhatnagar, R. K., 359
Bhattacharyya, B., 359
Blaschke, T. F., 316
Bleomhof, D. A., 283
Blouin, R. A., 261, 319
Bodor, N., 172
Boje, K. M., 655
Borchardt, R. T., 369
Boswell, G. W., 749
Bouwstra, J. A., 722
Bowles, S. K., 440
Boxenbaum, H., 201, 247
Brazzell, R. K., 261, 319
Breimer, D. D., 453
Breutzmann, D. A., 10
Brewster, M. E., 172
Brodsky, F. M., 1
Brooks, D. E., 749
Bucks, D. A. W., 313
Buechter, D. D., 253
Burke, B. A., 781
Burke, G. M., 183
Burke, P. J., 238
Byron, P. R., 36, 574

Cairns, T., 31
Caldwell, L. J., 533
Canafax, D. M., 781
Cannon, J. G., 359
Carey, T. E., 518
Cargill, R., 533
Carlin, A. S., 99
Carstensen, J. T., 387
Cascella, P. J., 803
Casper, A. G. T., 165
Cavrini, V., 709
Ceserani, R., 430
Chafetz, L., 247
Chalasinska, B., 61
Chan, R. L., 335
Chan, T. W., 523
Chang, S.-F., 718
Chang, Y. A., 359
Chappell, G. S., 803
Chatterjes, T., 359
Cheng, H., 57, 156
Chiang, C.-M., 377
Chiang, C.-C., 103
Chien, Y. W. 103, 718
Chin, C. L., 749
Chiou, W. L., 668
Chiu, A. T., 242
Cho, M. L., 352
Chu, Y.-Q., 680
Ciociola, A. A., 447
Cipolle, R. J., 781
Clarke, F. H., 660
Clifford, C. B., 749
Colombo, P., 488
Constantini, E. G., 10
Cook, J. A., 86, 196
Cortese, M., 587
Coutts, R. T., 40, 383
Cullander, C., 443

Dalby, R. N., 36
Davidson, G. W. R. III, 457
Davis, S. S., 226
de Angelis, R. J., 426
de Boer, A. G., 453
de Vries, M. A., 722
de Zeeuw, R. A., 283
DeLuca, P. P., 21, 421, 426
Dent, J., 598
Derendorf, H., 172, 509
DiPietra, A. M., 709
Dietz, N. J., 803
Disselhorst, D. J., 749
Donbrow, M., 178
Donohoe, B., 550
Doye, A. A., 749
Dressman, J. B., 272, 550

Edwards, D. J., 440
El-Yazigi, A., 220
Ellinwood, E. H., 365
Elmquist, W. R., 10
Elrod, L., 664
Embil, K., 387
Engle, K., 533
Ensing, K., 283
Ensminger, W. D., 518
Erdmann, G. R., 781
Estes, K. S., 172

Fales, H. M., 713
Fara, J. W., 165
Farraj, N. F., 226
Felgner, P. L., 759
Fix, J. A., 553, 587
Fleisher, D., 651
Fleitman, J. S., 759
Flynn, G. L., 377, 580
Flynn, J. R., 359
Fondacaro, J., 598
Foster, L. C., 528
Freter, K. R., 397
Fricke, S., 726
Fritzberg, A. R., 325
Fu, R. C.-C., 759
Fukunaga, K., 713
Fukushima, S., 741
Fukuyasu, T., 795
Fung, H.-L., 655
Fung, M.-C., 140

Galinsky, R. E., 61
Gallati, H., 472
Gallo, J. M., 300
Gardner, C. R., 533
Gatti, R., 709
Gautieri, R. F., 447
Gazzaniga, A., 488
Giacomini, K. M., 316, 465, 628
Gisclon, L. G., 465
Glikfeld, P., 443
Goodrich, S., 341
Gould, F. H., 781
Grass, G. M., 372
Greger, J. L., 501
Groves, M. J., 607, 776
Gruber, S. A., 781
Gu, L., 765
Gupta, S. K., 365
Guy, R. H., 313, 443, 660, 753
Gwilt, P. R., 196

Hadgraft, J., 753
Hadley, S. W., 325
Hall, I. H., 413
Handlon, A. L., 297
Hardens, M. A., 453
Harland, R. S., 482
Hashida, M., 309
Hashimoto, N., 266
Hassan, E. E., 300
Haughey, D. B., 10
Hayashi, M., 341, 786
Hayashi, Y., 741
Hein, W., 472
Hemphill, D. G., 10
Higaki, K., 309
Higashi, Y., 209
Higuchi, W. I., 566
Hinz, R. S., 443
Hirano, K., 266
Ho, C. S., 92
Ho, W., 335
Hochhaus, G., 232, 790
Hoener, B.-a., 434
Hoffman, A., 178
Holinej, J., 729
Hori, R., 694, 699
Horie, T., 786
Hostetler, C. K., 514
Houglum, J. E., 803
Howard, S., 495
Hrushesky, W. J. M., 781
Hsu, F.-H., 668
Hsyu, P.-H., 465
Huang, Y.-C., 103
Hussain, M. A., 44, 113, 242, 615
Huttenrauch, R., 726
Hynes, P. E., 781

Ichihashi, T., 266
IJzerman, A. P., 772
Ilumura, K., 694
in't Hout, W. G., 283
Inoue, A., 795
Inoue, M., 266
Inui, K.-i., 694, 699
Irie, T., 713
Ishizawa, T., 786

Jamali, F., 40, 53, 76, 123
Ju, L.-K., 92

0724-8741/88/1200-0809$06.00/0 © 1988 Plenum Publishing Corporation

Junginger, H. E., 722
Jusko, W. J., 156

Kamat, M. S., 421, 426
Kamiya, A., 694, 699
Kanke, M., 21
Karol, M. D., 341
Kato, M., 309
Kawaguchi, T., 741
Kellner, P. E., 639
Khoury, N., 495
Kikkoji, T., 694, 699
Kohler, M., 726
Kou, J. H., 592
Koval, C. A., 615
Kowarski, A. A., 245
Kowarski, C. R., 245
Koyama, Y., 426
Kozlowski, M. R., 236
Krauss, D., 107
Kunkel, S. L., 129

LaFargue, J., 335
Lalonde, R. L., 187
Larrick, J. W., 129
Lee, C.-S. C., 387
Lee, L.-J., 745
Lee, P. I., 592
Lee, T. M. L., 359
Lee, W., 528
Legg, B., 80
Leppert, P. S., 587
Levy, G., 401
Lidgate, D. M., 759
Lin, S., 245
Ling, T., 457
Long, J. P., 359

Magill, A., 214
Maibach, H. I., 313, 660
Manoukian, E., 16, 704
Markin, R. S., 201, 408
Martin, C. R., 220
Marvin, M. J., 457
Mauger, J. W., 495
Maybaum, J., 518
Mazzenga, G. C., 660
McNamara, P. J., 261, 319
Mehvar, R., 53, 76
Merkle, H. P., 689
Messner, S. L., 664
Michalek, L. M., 245
Mirabelli, C., 598
Mitra, A. K., 734
Mojaverian, P., 639
Mollmann, C., 509
Mollmann, H., 509, 623
Moore, L., 718
Mortada, L. M., 288
Mullersman, G., 172
Murakami, T., 209
Murray, A. J., 749
Murray, W. J., 201, 408
Mutschler, E., 107
Myrback, R. E., 165

Nakano, M., 741
Nakata, Y., 795
Nardi, D., 430
Narurkar, M. M., 734
Neff, J., 477
Nelson, W. L., 316
Nerenberg, C. A., 335
Nguyen, N.-A. T., 288, 634
Nilsson, E., 151
Nishihata, T., 738
Nishiura, A., 209
Niven, R. W., 574
Notari, R. E., 288, 634
Nyanda, A. M., 359

O'Yang, C., 214
Okor, R. S., 604
Ong, J. T. H., 16, 704
Oppenheimer, N. J., 297
Osawa, T., 421, 426
Ozturk, S. S., 272, 550

Palsson, B. O., 272, 550
Parr, G. D., 226
Pasutto, F. M., 40
Patel, R. A., 116
Patthy, A., 790
Peppas, N. A., 488
Pershe, R., 316
Petre, W. J., 482
Pietra, C., 430
Pitha, J., 713
Porter, P. A., 533
Porter, W., 387
Portner, M., 623
Poulos, T. L., 67
Powell, M. F., 214, 528
Prasad, V. K., 48, 99
Price, W. A., 242
Pushpala, S., 800

Rabatin, J. T., 781
Raehs, S. C., 689
Raggi, M. A., 709
Raykar, P. V., 140, 566
Reymond, J.-P., 673, 677
Ritz, J. A., 781
Rocci, M. L., 639
Rohdewald, P., 509, 623
Roorda, W. E., 722
Roosdorp, N., 800
Rosenberg, L. S., 514
Rowland, M., 80
Roy, S. D., 580
Russell, A. S., 40
Rutledge, D. R., 619
Ryan, F., 598
Ryrfeldt, A., 151
Rytting, J. H., 738

Sadée, W., 199, 232, 790
Sager, A. O., 48, 99
Sak, M., 655
Sakai, K., 738
Sanders, L. M., 457
Sandow, J., 689
Sandri, R., 477
Sangalli, M. E., 488
Santi, D. V., 790
Sato, T., 21
Savage, T. S., 31
Schjelderup, L., 236
Schmidt, W. F., 387
Schottelius, D. D., 183
Schroeder, H. G., 21
Schuirmann, D. J., 322
Schwietert, R., 790
Scieszka, J. F., 352
Segawa, T., 795
Semple, H. A., 383
Sezaki, H., 309
Shah, V. P., 322
Shapira, A., 518
Shefter, E., 44, 113, 242, 615
Shibata, T., 694
Shiga, M., 341
Shiu, G. K., 48, 99
Shum, L., 57
Shumaker, R. C., 247
Siegmund, E. G., 31
Sieve, R. M., 803
Simmons, J. E., 99
Simmons, R. L., 781
Singh, N. N., 40
Sinko, P. J., 645, 651
Skelly, J. P., 48, 99, 322
Smith, D. E., 86, 745
Smith, P., 598
Smithers, J., 684
Snow, J. W., 729
Spahn, H., 107
Staubus, A. E., 57
Steffen, H., 472
Stetson, P. L., 518
Stevens, H. N. E., 226
Straka, R. J., 187
Streeter, A. J., 434
Strickley, R. G., 765
Sucker, H., 673, 677
Sun, J. X.-S., 387
Supersaxo, A., 472
Svensson, C. K., 437
Svensson, L.-A., 151
Sweetana, S. A., 372
Szlaczky, M., 619

Takahashi, K., 738
Takeda, R., 795
Tam, Y. K., 383
Tanaka, H., 266
Tang-Liu, D. D. S., 238, 477
Taylor, R. B., 250
Teagarden, D. L., 482
Teng, C.-L. D., 776
Testa, R., 430
Thomas, D. A., 190
Thompson, G. A., 247
Timmermans, P. B., 242
Tin, S., 383
Tomita, M., 341, 786
Tunek, A., 151
Tyle, P., 251

Uekama, K., 713

Valdivieso, L., 316
van Bree, J. B. M. M., 369
van der Lende, J., 283
van Hoogdalem, E. J., 453
Vasavada, R. C., 116
Velagapudi, R. B., 48
Veng-Pedersen, P., 183
Verho, M., 509
Vlasses, P. H., 639
Vonderscher, J., 677

Wagenknecht, D. M., 514
Wagner, J. G., 518
Wainer, I. W., 187, 680
Wang, J. C. T., 92
Ware, J. A., 437
Webb, A. S., 335
Weiner, N., 377
Weissman, A., 236

Wester, D. W., 325
Wetterlin, K., 506
Whatley, J., 759
Whittico, M. T., 628
Wiedmann, T., 607
Williams, N. A., 193
Wilson, D. R., 660
Wirth, K., 689
Wollner, I. S., 518
Wong, O. T., 413
Wurster, D. E., 183
Wyrick, S. D., 413

Xu, H., 103

Yamada, H., 266
Yamamoto, E., 266
Yasuhara, M., 401
Yata, N., 209
Yoshida, A., 713
Yu, C.-D., 800
Yu, D., 457

Zhang, A., 607
Zimmerman, C. L., 120
Zolezio, H., 477
Zon, G., 539

Subject Index to Volume 5 (1988)

3′-azidothymidine (AZT), 297
5-fluoro-2′-deoxyuridine, see FUdR
5-fluorouracil absorption, Ussing chamber analysis, 598
5-iodo-2′-deoxyuridine, see IDU
6-mercaptopurine, intraarterial infusion, 781
6-mercaptopurine, pharmacokinetics, 781
1,4-dihydropyridines, 655
absorption enhancers, colonic, 341
absorption rate constant, apparent first-order, 57
absorption rates, LOTUS 123 spreadsheet for, 247
absorption, food effects on theophylline, 48
absorption, nasal, 689
ACE inhibitor RS-10029, degradation kinetics, 765
ACE inhibitor RS-10029, degradation products, 765
acetaminophen metabolism, effects of taurolithocholate, 61
acetaminophen, glucuronidation, 61
acetaminophen, sulfation, 61
acidosis, and gallapomil toxicity, 619
acrylate methacrylate copolymers, structure and permeability, 604
activated charcoal, adsorption of phenobarbital, 183
activation energy, epimerization in frozen solution, 266
adjuvant effects of bactitracin, 689
adjuvant effects of taurodihydrofusidate, 689
adjuvants, formulation, 523
adjuvants, reversible interaction with RBCs, 729
adjuvants, thermal interactions with RBCs, 729
adsorption, of phenobarbital by activated charcoal, 183
aerosol absorption from respiratory tract, 574
aerosol, inhalation and particle size, 36
aggregation mechanism, BCG vaccine, 607
aggregation number, BCG vaccine, 607
agonist-induced down-regulation, 795
albumin, cocaine binding, 440
aldose reductase inhibitor (AL-01576), protein binding, 319
  AL01576, 261
  pH-dependent binding, 319
  serum binding in diabetes, 261
allometric equation, animal scale-up in pharmacokinetics, 668
alpha-1 glycoprotein, gallapomil binding, 619
alpha-1-acid glycoprotein (AAG), cocaine binding, 440
alpha-adrenergic receptors, spasmolytic binding studies, 430
alpha$_1$-antitrypsin, recombinant, see rAAT
alveolar macrophage, quinidine accumulation in, 209
amino acid analysis in plasma, HPLC, 684
amino acid carrier, bovine brain endothelial cells, 369
amiodarone metabolism, 709
amiodarone, HPLC, 709
ampicillin, bioavailability, 634
ampicillin, prodrugs for improved shelflife, 288
anabolic steroids, separation and identification, 31
analysis, coupled steady state and nonsteady state, 92
angiotensin converting enzyme (ACE) inhibitor, RS-10029, 765
animal models, cat esophagus, 165
  cat gastric mucosa, 165
  gastrointestinal irritation, 165
  rabbit colon, 165
animal scale-up in pharmacokinetics, 668
anthralin products (1%), oxygen diffusion studies, 92
antiarrhythmic agent ACC-9358, HPLC, 190
anticholinergic, oxyphencyclimine enantiomers, 236
antihypertensive activity, quinazolinone analogues, 242
antihypertensive drugs, whole blood analysis, 383
antimuscarinic activity of oxyphencyclimine, 236
antineoplastic agents, carmustine and lomustine, 220
antioxidants, cellular, 253
antipyrine clearance, dextromethorphan pretreatment, 437
antipyrine, pharmacokinetics, 437
antiretroviral drugs, AZT and DDT, 297
antiretroviral drugs, kinetics and biomedical impact, 297
antitussive agents, dextromethorphan pharmacokinetics, 437
ascorbate, effects on transdermal penetration, 738
asymmetric permeability, composite films, 604
AUC, i.v. plasma concentration, 57
  oral plasma concentration, 57
  tissue sampling compartments, 238
avidin, crosslinking with κ-receptor, 790
azathioprine, 6-mercaptopurine metabolite of, 781
azido drugs, biological reduction, 297
azone, percutaneous transport of isoproterenol, 116
  effect on ocular levobunolol absorption, 238
AZT, biological reduction, 297

bacampicillin, bioavailability, 634
bacampicillin, prodrugs for improved shelflife, 288
Bacillus Calmette Guerin (BCG) vaccine, size characterization, 607
bacitracin, adjuvant effect on nasal absorption, 689
  mucosal tolerance of, 689
baclofen, enantiospecific HPLC, 107
  fluoro analogue, enantiospecific HPLC, 107
  transport across brain endothelial cells, 369
  urinary excretion, 107
bambuterol, biotransformation in lung, 151
  uptake in lung, 151
basal metabolic rate, to correlate plasma clearance, 668
behavioral anomalies, and ethanol, 447
benzodiazepine receptor binding affinities, 408
benzodiazepines, pharmacokinetics, 201
  QSAR for endogenous, 408
beta-adrenergic receptors, spasmolytic binding studies, 430
β_h-endorphin, biotin-avidin ELISA, 232
bile acid metabolism, effects of taurolithocholate, 61
bioanalysis, dopamine receptors, 283
bioassay, intravenous for synthetic insulins, 245
bioavailability, beta estradiol, 44
  cyclosporin A and erythrocyte binding, 80
  intersubject variability, 322
  naltrexone salicylate, 113
  ocular levobunolol, 238
  oral progabide, effect of gastric pH on, 226
  theophylline, 48
biocytin-dynorphin, κ-opioid receptor probe, 790
bioequivalence, intersubject variability, 322
  tissue sampling compartments, 238
biotin-avidin ELISA, β_h-endorphin, 232
biotinylated receptor lipid, 790
bitterless prodrugs, buccal delivery of opioid analgesics, 615
bladder, spasmolytics, 430
blood plasma concentration, recombinant human interferon, 472
blood-brain barrier, carrier mediated transport, 369
  estradiol delivery, 172
body surface area, to correlate plasma clearance, 668
boundary layer, mathematical model, 645
bovine brain, culture of endothelial cells, 369
brain DNA synthesis, and fetal alcohol syndrome, 447
brain-specific drug delivery, redox carriers, 172
bromodeoxyuridine (BUdR) incorporation *in vitro*, 518
bronchodilator, metered-dose powder inhaler, 506
  bambuterol, 151
  terbutaline, 151
buccal absorption, opioid analgesics, 615
buffer effect on dissolution, 272
bumetanide, acute tolerance of, 86
  constant-rate infusion studies, 86
  pharmacodynamics, 86
  pharmacokinetics, 86
buserelin, nasal absorption with adjuvants, 689

calcium magnesium supplements, mineral metabolism, 501
calcium matabolism, calcium supplements and yogurt, 501

0724-8741/88/1200-0812$06.00/0 © 1988 Plenum Publishing Corporation

cancer, diagnostics, 325
radiotherapy, 325
capillary endothelial cells, drug targeting, 300
caprate, sodium, colonic absorption promoter, 786
carbadopa, duodenal administration, 587
pharmacokinetics, 578
rectal administration, 587
effect on systemic L-dopa levels, 587
carmustine (BCNU), GC and thermionic N-P specific detection, 220
carmustine, stability and pharmacokinetics, 220
carrier systems, receptor-mediated magnetic chitosan, 300
carrier-mediated absorption, fraction dose absorbed, 651
intestinal membrane, 651
cat esophagus model, 165
cat gastric mucosa model, 165
catalase, oxygen radical scavenging, 253
catalytic mechanism, bacterial cytochrome P450, 67
cefazolin crystallinity, IR spectrometry, 426
X-ray diffractometry, 426
cefazolin sodium pseudopolymorphs, 421
crystallinity of freezed dried, 421
hygroscopicity of, 421
cefmetazole, colonic absorption enhancers, 341
cefoxitin, rectal absorption enhancement, 453
cephalosporins, intrinsic membrane absorption parameters, 645
cephalosporins, oral absorption, 645
cerebrospinal fluid, 401
cerebrospinal fluid, cimetidine elimination from, 628
chelated mineral supplements, retention and digestion, 501
chemical delivery system, 172
chemical kinetics, 288
chemical structure/skin irritation, 660
chemotherapeutic agents, antisense oligonucleotides, 539
chiral drugs, enantiomeric inversion, 76
first-pass metabolism, 76
chloride ion excretion, and furosemide, 694
chlorzoxazone, in CSF and serum, 401
pharmacodynamics, 401
skeletal muscle relaxant, 401
cholestasis, taurolithocholate induced, 61
cholesterol, membrane permeability, 309
choline uptake, inhibition by hemicholinium, 359
choroid plexus, cimetidine transport, 628
cimetidine, dissolution, 488
elimination from cerebrospinal fluid, 628
renal transport, 465
clearance, cimetidine from cerebrospinal fluid, 628
CNS, substance P down-regulation, 795
cocaine, classes of binding sites, 440
codeine, solubility parameters, 580
colon permeability, passive absorption mechanism, 645
colonic absorption promoters, sodium caprate and sodium caprylate, 786
colonic absorption, cefmatazole, 341
inulin, 341
colonic drug absorption, 341
colonic drug absorption, transcellular permeation, 786
colonic pore radius, drug absorption, 341
colony forming units (CFU), BCG vaccine, 607
compactional activity, effect on urease activity, 776
compartmental model, nonlinear analysis, 156
complexation, enhancement of nifedipine solubility, 655
composite film pore structure, acrylate methacrylate copolymers, 604
composite films, asymmetric permeability, 604
composite films, pore structure, 604
computer program, drug absorption rates, 247
computer simulation, utilization time, 634
controlled drug delivery, microspheres, 21
controlled release dosage forms, effect of compaction, 776
controlled release drug dosage forms, pHEMA hydrogels, 722
controlled release, drug/polymer matrix, 488
microsphere release profiles, 178
theophylline, 48
convection diffusion model, 495
convolution integral, 57
corticosteroids, topical, timobestone acetate, 704
Coulter, size analysis comparison, 607
creams, topical semisolid and oxygen diffusion studies, 92
crystal structure, bacterial cytochrome P450, 67
crystalline modification, vaccine adjuvants, 523
crystalline transformation, cefazolin sodium, 421
crystallinity, of freeze-dried cefazolin sodium, 421
cumulative lymph recovery, recombinant human interferon, 472
cutaneous blood, drug monitoring, 477
cyanide antidote, methemoglobin, 749
cyanide poisoning, pharmacokinetics, 749
cyclic imides, hypolipidemic agents, 413
cyclodextrin derivatives, water soluble, amorphous, 713
water soluble, and pharmaceutical usefulness, 713
cyclosporin, *in vitro* model of intestinal absorption, 673
in vivo model of intestinal absorption, 677
saturable binding to erythrocytes, 80
therapeutic drug monitoring, 80
cytochrome P450, catalytic mechanism of bacterial, 67
crystal structure of bacterial, 67
dynamics of substrate binding, 67
inhibitor design of bacterial, 67
cytokines, 129
cytotoxicity, IDU prodrugs, 734

decomposition products, stability indicating assay, 250
deconvolution, model independent approach, 347
to quantify drug dissolution, 574
degradation kinetics, parenteral prodrugs, 288
derivative spectrophotometry, background absorption by excipients, 709
derivative spectrophotometry, first and second order, 709
desethylamiodarone, HPLC, 709
detirelix pharmacokinetics, 335
dextromethorphan, antipyrine clearance, 437
pharmacokinetics, 437
di(2-ethylhexyl)phthalate, HPLC, 10
pharmacokinetics, 10
diabetes, glucosylated albumin, 261
serum protein binding of drugs, 261
diagnostic localization, radiolabeled antibodies, 325
diastereoisomer separation, HPLC for fenoprofen enantiomers, 53
diazepam, serum binding in diabetes, 261
diclofenac sodium, dissolution, 488
diclofenac transdermal penetration, effect of ascorbate on, 738
effects of dithiothreitol on, 738
differential scanning calorimetry, RBCs, 729
diffusion cell, gastrointestinal tissue, 372
iontophoretic for *in vitro* studies, 443
diffusion characteristics of hydrogels, 592
diffusion transport mechanisms, oxygen in creams, 92
diffusion, from 2-phase emulsion type ointment, 16
topical thin applications, 377
difluoromethylornithine (DFMO), HPLC, 684
dihydropyridines, 172
diisopropylfluorophosphate, esterase inhibition, 623
diprophylline, dissolution, 488
disintegration time, enteric coating, 550
disopyramide, stereoselective binding, 316
dissolution, drug/polymer matrix, 488
dithiothreitol (DTT), 297
effects on transdermal penetration, 738
diuretic response, quantitative measure of, 694
DNA binding, nitrenium ion to nitrofurazone, 434
dopamine agonist N-0437, radioreceptor assay, 283
dopamine receptors, radioreceptor assay, 283
dopaminergic bioactivity assay, 283
dosage form design, gastric retention times, 533
dosage form design, physical parameters, 533
dose accountability, percutaneous absorption, 313
down-regulation, agonist-induced for substance P, 795
drug delivery system, porous biodegradable microspheres, 21
implantable pump for intrarenal infusion, 781
liposomes as, 759

drug delivery, iontophoresis, 251
drug design, 397
  P450 as model system for, 67
drug dissolution, buffer effects, 272
  film model for, 272
  ionization effects in buffered, 272
  ionization effects in unbuffered, 272
drug metabolism, enzyme induced dextromethorphan, 437
drug monitoring, cutaneous blood, 477
drug screening, systematic, 397
drug solubilization, liposome system for, 759
drug stability testing, interpretation, 249
drug stability, initial rate method, 249, 250
drug transport, topical thin applications, 377
drug/polymer matrix swelling and dissolution, 488
drugs, sparingly soluble, ionization constants, 772
  sparingly soluble, limiting solubilities, 772
DTT, biological reduction, 297

effects of gender, posture, and age, 639
electrode material for iontophoresis, 251
elimination of hydrocarbons, P450, 67
ELISA, β_h-endorphin, 232
elixirs, phenobarbital, 803
emulsion-type ointment, two-phase, 16
enantiomeric inversion, chiral NSAIDs, 76
  ibuprofen, 40
enantioselective HPLC for warfarin, 680
endothelial cells, blood-brain barrier transport, 369
enhancement, skin absorption, 753
enzymatic hydrolysis of FUdR esters, 741
enzyme induction, dextromethorphan, 437
ephedrine diastereoisomers, thermodynamics, 391
ephedrine enantiomers, thermodynamics, 391
ephedrine, solubility, 391
epimerization in frozen solution, activation energy, 266
epimerization, moxaolactam in frozen solution, 266
equilibrium distribution model for micellar solubilization, 704
erythrocytes, saturable binding of cyclosporin to, 80
esmolol, secondary buffer system from degradation, 514
ester prodrugs, enzyme specificity, 741
  hydrolysis of, 741
esterase inhibition, diisopropylfluorophosphate, 623
estradiol, CNS-directed, 172
  first pass metabolism, 44
  oral bioavailability, 44
  prodrugs, 44
ethanol-water mixtures, solubility equation, 193

fatty acids, rectal absorption enhancement of medium chain, 453
fenoprofen enantiomers, pharmacokinetics, 53
fenoprofen, HPLC for diastereomeric separation, 53
fentanyl, solubility parameters, 580
fetal alcohol syndrome, brain DNA synthesis, 447
film model for dissolution, 272
  absorption, 651
  release kinetics, 550
first-pass metabolism, beta estradiol, 44
  chiral NSAIDs, 76
fluid mechanics and dissolution rate, 495
fluorescein, dissolution in isolated lung, 574
fluorescence polarization, for membrane perturbation studies, 786
flurbiprofen enantiomers, HPLC, 123
food effects, theophylline controlled release, 48
formulation design, enteric coating, 550
formulation, effect on particle size distribution, 36
  oxygen sensitive drugs, 92
  particulate rAAT, 800
fraction dose absorbed, carrier-mediated compounds, 651
  passive absorption, 651
free volume, hydrogels, 592
freeze drying, cefazolin sodium, 421, 426
Freundlich model, 183
frozen solution, epimerization in, 266
FUdR ester prodrugs, nonenzymatic and enzymatic hydrolysis of, 741

functional group contributions in transport through SC, 566
furosemide, effect on urinary electrolyte excretion, 694
  increased response during acute renal failure, 699
  urinary excretion of, with dopamine coadministration, 699

gallapomil protein binding, effect of pH, 619
gas chromatography, see GC
gas chromatography, stereospecific assay for ibuprofen, 40
gastric emptying, nondisintegrating geometric shapes, 533
  pharmacokinetics, 533
gastric residence time, effects of gender, posture, and age on, 639
gastric transit time, Heidelberg capsule, 639
  radiotelemetry, 639
gastrointestinal irritation, 165
  doxycycline, 165
  potassium chloride, 165
  propranolol, 165
gastrointestinal permeability, *in vitro* measurement, 372
gastrointestinal therapeutics system, 165
gastrointestinal tissue, diffusion cell, 372
GC, capillary with electron capture for GTN metabolites, 99
  of BCNU and CCNU, 220
genetic diseases, 199
glucocorticoid receptors, in human synovial tissue, 623
glucocorticoid-21-esters, relative receptor affinity, 623
glucocorticoids, comparative pharmacokinetics at high doses, 509
glucose monitor in dog, intravenous, 245
glucosylated albumin, in diabetes, 261
glucuronidation, acetaminophen, 61
glycerides, medium chain and membrane permeability, 309
gonadorelin, nasal absorption with adjuvants, 689
graph theoretical approach, endogenous benzodiazepines, 408
guanidino moiety, antihypertensive activity, 242
gut metabolism ibuprofen enantiomers, 40

Heidelberg capsule, gastric transit time, 639
helix-coil equilibrium in gelatin microcapsules, 726
hemicholinium congeners, structure-activity relationship, 359
heparin complex with chitosan microspheres, 300
hepatic conjugation, and taurolithochlate, 61
hereditary diseases, 199
hexamethylene lauramide, disposition, 477
hexamethylene lauramide, skin penetration enhancer, 477
HIAC/Royco, size analysis comparison, 607
high density lipoprotein (HDL) receptor activity, 413
high pressure liquid chromatography, see HPLC
HPLC, with electrochemical detection, spectinomycin, 664
  with electrochemical detection, trobicin, 664
  achiral/chiral warfarin enantiomers, 680
  amino acid analysis in plasma, 684
  amiodarone, 709
  antiarrhythmic agent ACC-9358, 190
  chiral stationary phase, 187
  CNS-directed estrodiol, 172
  desethylamiodarone, 709
  di(2-ethylhexyl)phthalate, 10
  difluoromethylornithine (DFMO), 684
  enantiospecific for baclofen, 107
  fenoprofen diastereomeric separation, 53
  flurbiprofen enantiomers, 123
  hydralazine, 383
  muramyldipeptide, 528
  phenobarbital, 803
  precolumn derivatization with o-phthalaldehyde, 684
  precolumn enrichment, 172
  propanaolol enantiomers, 187
  quazepam metabolites, 365
  whole blood analysis, 383
human plasma, HPLC for antiarrhythics in, 190
human serum albumin, gallapomil binding, 619
Humulin R, biological activity compared to Novolin R, 245
Humulin R, intravenous bioassay for, 245
hydralazine, HPLC, 383
  p-nitrobenzaldehyde derivatization, 383
hydrocortisone alcohol, dissolution rate studies, 495
hydrocortisone esters, partition coefficients in stratum corneum, 566

uptake by stratum corneum, 140
hydrocortisone, saliva analysis for endogenous, 509
skin penetration enhancement, 477
hydrogels, diffusion characteristics, 592
free volume, 592
pH-dependent swelling, 592
poly(hydroxyethyl methacrylate-CO-methacrylic acid), 592
hydrolysis kinetics, bacampicillin, 288
talampicillin, 288
hydromorphone, bioavailability, 718
intravenous administration, 718
nasal administration, 718
oral administration, 718
pharmacokinetics, 718
solubility parameters, 580
transdermal administration, 718
hygroscopicity, cefazolin sodium, 421
hypolipidemic agents, cyclic imides, 413
lipoprotein degradation, 413
receptor activity, 413

i.v. coadministration of carbadopa and L-dopa, 587
ibuprofen enantiomers, pharmacokinetics, 40
ibuprofen, enantiomeric inversion, 40, 76
gut metabolism, 40
pharmacokinetics, 76
presystemic inversion, 40
stereospecific gas chromatographic technique, 40
IDU prodrugs, cytotoxicity, 734
physicochemical properties, 734
synthesis, 734
immunoinflammatory response, 129
immunosuppressive drug administration, intraarterial, 781
immunotherapy, and monoclonal antibodies for, 1
in vitro apparatus, gastrointestinal tissue permeability, 372
in vitro model, cyclosporin intestinal absorption, 673
in vivo model, cyclosporin intestinal absorption, 677
indigestible solid, Heidelberg capsule, 639
indomethacin microspheres, 178
indomethacin, transdermal administration, 103
inflammation, interleukin 1, 129
tumor necrosis factor, 129
infrared (IR), cefazolin sodium, 426
inhalation aerosol, output particle size distribution, 36
inhaler, metered-dose powder, 506
inhibitor design, bacterial cytochrome P450, 67
initial rate method, drug stability, 249, 250
inspiratory flow rate, and metered-dose powder inhaler, 506
insulin, synthetic human, 245
interleukin 1 and inflammation, 129
intersubject variability, bioavailability/bioequivalence, 322
intestinal absorption, 5-fluorouracil, 598
in vitro model for cyclosporin, 673
in vivo model for cyclosporin, 677
intestinal membrane permeability, 651
intestinal metabolism, Ussing chamber analysis, 598
intestinal transport, Ussing chamber analysis, 598
intraarterial infusion of immunosuppressive drugs, 781
intragastric pH measurement via radiotelemetry, 639
intravenous administration of hydromorphone, pharmacokinetics, 718
intrinsic membrane absorption parameters, mathematical model, 645
inulin, colonic absorption enhancers, 341
ionization constants, using potentiometric titration, 772
iontophoresis, diffusion cell for, 443
electrode material, 251
isoproterenol, partition coefficient, 116
percutaneous transport, 116
solubility, 116
stability, 116

κ-opioid receptor probe, biocytin-dynorphin, 790
ketorolac, percutaneous absorption, 457
kidney, membrane transport, 465
kinetics of release, film model, 550
kinetics of replacement, thymidine by BUdR, 518

L-dopa, effect of carbadopa on systemic levels, 587
Langmuir equation, 183
levobunolol, effect of azone on ocular absorption, 238
linear free-energy relationships, nifedipine solubility, 655
lipid digestion, cyclosporin lipid vehicle, 673, 677
lipid domains, in stratum corneum, 140
lipid emulsion, prostaglandin E_1, 482
lipid peroxidation, enzyme mediated repair, 253
oxygen free radicals, 253
lipid regulatory enzymes, 413
lipid uptake, stratum corneum, 566
lipid vehicle, cyclosporin intestinal absorption, 673, 677
lipophilic drug delivery systems, 759
liposomal uptake, membrane permeability studies, 309
liposomes as particulate drug carriers, 352
liposomes, drug delivery systems, 759
lomustine (CCNU), GC and thermionic N-P specific detection, 220
stability and pharmacokinetics, 220
lonapalene, antipsoriatic application, 16
in two phase emulsion-type ointment, 16
loop diuretics, quantitative measure of diuretic response, 694
LOTUS 123, spreadsheet for absorption rates, 247
low density lipoprotein (LDL) receptor activity, 413
lucifer yellow CH, human neutrophilic uptake, 352
lung biotransformation of bambuterol, 151
lung, cellular and subcellular distribution of quinidine in, 209
drug dissolution or release, 574
luteinizing hormone-releasing hormone (LHRH), 689
agonist, 689
antagonist, 335
lymph concentration, recombinant human interferon, 472

magnesium calcium supplements, mineral metabolism, 501
mass balance, percutaneous absorption, 313
mass spectrometry, collision-activated dissociation, 31
mathematical model, drug/polymer matrix analysis, 488
intrinsic membrane absorption parameters, 645
mean residence time, Michaelis-Menten elimination, 156
Michaelis-Menten kinetics, 196
medicinal chemistry, drug design, 397
membrane permeability, medium chain glycerides, 309
membrane perturbation, by sodium caprate, 786
fluorescence polarization, 786
membranes, adjuvant effects on RBC, 729
membranous microviscosity, medium chain glycerides, 309
meperidine, solubility parameters, 580
metabolic derivatives of progabide, 226
metabolism, bambuterol in lung, 151
metabolite formation, pharmacokinetics, 347
metal ions and iontophoresis, 251
methemoglobin, cyanide antidote, 749
methylprednisolone hemisuccinate, pharmacokinetics, 509
methylprednisolone phosphate, pharmacokinetics, 509
micellar solubilization, equilibrium distribution model, 704
micelle formation, change of water structure and, 726
micelles, critical micelle concentration determination, 726
Michaelis-Menten elimination, mean residence time, 156
one compartment, 196
microcapsule disintegration, and helix-coil equilibrium, 726
microspheres, controlled release, 21
heparin complexing with chitosan, 300
indomethacin, 178
magnetic chitosan and receptor targeting, 300
poly(glycolic) acid, 21
porous as drug delivery system, 21
processing conditions, 21
release profiles, 178
solvent removal techniques, 21
microviscosity, medium chain glycerides, 309
micturitional disorders, spasmolytics, 430
mini-swine, model for food effects on theophylline absorption, 48
mixed solvents, solubility equation, 193
model independent approach to deconvolution, 347

moment analysis, 57
  compared to nonlinear analysis, 156
monoclonal antibodies, radionuclide selection for, 325
  therapeutic applications, 1
morphine, solubility parameters, 580
moxalactam, epimerization in frozen solution, 266
muramyldipeptide, amorphous and crystalline characterization, 523
  HPLC, 528
  hydrolysis kinetics, 528
  mutarotation, 523
  parenteral formulation, 528
  pH of maximum stability, 528
  thermal reactivity, 528
muscarinic receptors, spasmolytic binding studies, 430
mutarotation, muramyldipeptide, 523
Mycobacterium bovis BCG (*Bacillus* Calmette Guérin), 607

nalbuphine, bitterless prodrugs of, 615
naltrexone salicylate, bioavailability, 113
naltrexone, prodrug bioavailability, 113
  prodrug pharmacokinetics, 113
  prodrug synthesis, 113
narcotic analgesics, transdermal delivery, 580
  solubility parameters, 580
narcotic antagonist, buccal absorption, 615
nasal absorption, bacitracin as adjuvant for, 689
  buserelin, 689
  gonadorelin, 689
  taurodihydrofusidate as adjuvant for, 689
nasal administration of hydromorphone, pharmacokinetics, 718
  of peptide drugs, 689
nephrocalcinosis, calcium phosphate dibasic, 501
neuromuscular inhibition, hemicholinium, 359
neutrophils, phagocytosis, 352
  pinocytosis, 352
  targets for drug delivery, 352
nicardipine, percutaneous absorption, 457
nifedipine solubility, enhancement via complexation, 655
  complexation with substituted phenolic ligands, 655
nitrenium ion, DNA binding to nitrofurazone, 434
nitrofurazone, DNA binding of nitrenium ion, 434
nitroglycerin denitration products, capillary GC analysis, 99
NMR, ^{13}C cross-polarization/magic angle spinning, 611
NMR, solid state for skin hydration, 611
noncompartmental analysis without theoretical approximation, 57
nonlinear regression analysis, 57
nonsteroidal antiinflammatory drugs, chiral, 76
  see NSAIDs
nonsteroidal antipsoriatic agent, lonapalene, 16
Novolin R, biological activity compared to Humulin R, 245
Novolin R, intravenous bioassay for, 245
NSAIDs, antipsoriatic application, 16
  enantiomeric inversion, 76
  fenoprofen, 53
  first-pass metabolism of chiral, 76
  pharmacokinetics of chiral, 76
nuclear magnetic resonance, see NMR

occlusion, percutaneous absorption, 313
ointment, 2-phase emulsion type, 16
  USP XXI hydrophilic, oxygen diffusion study, 92
oligonucleotide analogues, translation arrest, 539
one-compartment model, Michaelis-Menten kinetics, 196
opiate receptors, spasmolytic binding studies, 430
opioid analgesics, buccal absorption, 615
opioids, solubility parameters, 580
oral absorption, β-lactam antibiotics, 645
  cephalosporins, 645
oral administration of hydromorphone, pharmacokinetics, 718
oral administration, utilization time, 634
organic cation transport, 465
oxydative enzyme activity, paralysis time, 401
oxygen diffusion studies, anthralin products (1%), 92
oxygen diffusion transport mechanism, creams, 92
oxygen diffusion, coupled steady state and nonsteady state, 92
oxygen free radical scavenging enzymes, 253
oxygen free radicals, paraquat toxicity, 253
  toxic effects, 253
oxygen sensitive drugs, formulation design, 92
oxyphencyclimine enantiomers, antimuscarinic activity, 236
oxyphencyclimine enantiomers, relative potency, 236

PAH, renal metabolism, 745
PAH, renal transport, 745
para-aminohippurate, see PAH
paracellular permeation, colonic drug absorption, 341
  pore radius, 341
paralysis time, oxidative enzyme activity, 401
paraquat toxicity, oxygen free radicals, 253
parenteral administration, recombinant human interferon, 472
  utilization time, 634
parenteral prodrugs, hydrolysis of, 288
particulate drug carriers, liposomes as, 352
  isoproterenol, 116
  in stratum corneum, 566
  prostaglandin E_1, 482
  solutes into stratum corneum, 140
passive absorption mechanism, colon, 645
  fraction dose absorbed, 651
  intestinal membrane, 651
penetrant physical chemistry, 753
penetration enhancer, hexamethylene lauramide, 477
  azone, 238
  simultaneous application, 457
peptide drugs, ACE inhibitor, 765
  nasal administration, 689
percutaneous absorption, classical diffusion model, 753
  dose accountability, 313
  ketorolac, 457
  mass balance, 313
  nicardipine, 457
  nonocclusive, 313
  simple kinetic analysis, 753
percutaneous penetration, physicochemical aspects, 753
percutaneous transport, isoproterenol, 116
permeation routes, transcellular, 786
pH change, controlled by secondary buffer system, 514
pH profiles, 288
pH, skin permeation, 660
pH-dependent binding, aldose reductase inhibitor, 319
pH-dependent swelling of hydrogels, 592
phagocytosis, human neutrophils, 352
pharmacodynamics, bumetanide, 86
  chorzoxazone, 401
  phenylpropanolamine, 120
  zoxazolamine, 401
pharmacokinetics, 6-mercaptopurine (6-MP),781
  animal scale-up in, 668
  benzodiazepines, 201
  bumetanide, 86
  carmustine and lomustine, 220
  chiral NSAIDs, 76
  cimetidine, 628
  cyanide poisoning, 749
  deconvolution for metabolite formation, 347
  detirelix (LHRL antagonist), 335
  dextromethorphan, 437
  di(2-ethylhexyl)phthalate, 10
  disopyramide stereoisomers, 316
  fenoprofen enantiomers, 53
  gastric emptying, 533
  glucocorticoids at high doses, 509
  ibuprofen enantiomers, 40
  LOTUS 123 spreadsheet for absorption rates, 247
  mean residence time, 156, 196
  methylprednisolone hemisuccinate, 509
  methylprednisolone phosphate, 509
  Michaelis-Menten elimination, 156
  naltrexone salicylate, 113
  phenprobamate, 387

phenylpropanolamine, 120
quazepam metabolites, 365
renally transported drugs, 465
topological approach, 201
phase distribution pH dependent of prostaglandin E_1, 482
phase-volume ratio, 92
pHEMA (polyhydroxy ethyl methacrylate), 722
pHEMA hydrogels, elastic solution, 722
glass transition, 722
melting enthalpy, 722
thermal analysis of, 722
phenobarbital, adsorption, 183
alternatives for elixirs, 803
dosage form stabilities, 803
HPLC, 803
solubility, 803
phenol red, membrane permeability studies, 309
phenprobamate, time-dependent kinetics, 387
phenylpropanolamine disposition, urinary pH modification, 120
phenylpropanolamine, drug interactions, 120
pharmacodynamics, 120
pharmacokinetics, 120
renal tubular secretion, 120
phenytoin, serum binding in diabetes, 261
phosphatidylserine, effect on quinidine distribution in lung, 209
pinocytosis, fluid-phase of human neutrophils, 352
piretanide, effect on urinary electrolyte excretion, 694
pKa, relation to skin irritation, 660
plasma clearance, correlation between humans and rats, 668
plasma membrane, quinidine accumulation in, 209
plasma proteins, binding of disopyramide, 316
poly hydroxy ethyl methacrylate, see pHEMA
poly(glycolic) acid microspheres, 21
polymer matrix swelling, 488
potassium ion excretion, and furosemide, 694
potentiometric titration, antidepressants, 772
nucleside transport inhibitors, 772
sparingly soluble drugs, 772
presystemic inversion, ibuprofen enantiomers, 40
procainamide metabolites, pharmacokinetics, 347
prodrug design, 634
prodrug synthesis, naltrexone salicylate, 113
prodrugs for buccal delivery of opioid analgesics, 615
prodrugs, beta estradiol, 44
improved shelflife for parenterals, 288
improvement in shelf life, 634
progabide, oral bioavailability and gastric pH, 226
stability and solubility, 226
propanolol, enantioselective HPLC, 187
detection of serum levels, 187
serum binding in diabetes, 261
prostacyclin analogue degradation, alkene hydration, 214
pH effect, 214
proton transer, 214
prostacyclin analogue lactonization, 214
prostacyclin analogues, stability, 214
prostaglandin E_1, lipid emulsion, 482
partition coefficients, 482
pH dependent phase distribution, 482
protein aggregation, rAAT, 800
protein binding, cocaine, 440
pH dependence, 319
protein domains, in stratum corneum, 140
protein drugs, controlled release forms, 776
monoclonal antibodies as, 1
protein thiol, effects on transdermal penetration, 738
protein uptake, stratum corneum, 566
proximal tubule transport, 465
pseudopolymorphs, hygroscopicity of cefazolin sodium, 421
psoriasis, NSAIDs for, 16
pump, intrarenal infusion, 781
pyridinium salts, quaternary, 172

QSAR, benzodiazepines, 201
QSAR, structural similarity of 1,4-benzodiazepines, 408
quantitative structure-sctivity analysis, see QSAR
quazepam metabolites, pharmacokinetics, 365
quazepam, sublingual administration, 365
quinazolinone analogues, antihypertensive activity of, 242
quinazolinones, synthesis of 2-substituted 4(3H)-, 242
quinidine distribution, role of phosphatidylserine, 209
quinidine, distribution in lung, 209
in alveolar macrophages, 209
in plasma membrane of lung, 209

rAAT, particulate formation, 800
physical stability of, 800
protein aggregation, 800
shelf life prediction of injectable, 800
rabbit colon model, 165
radionuclides, tumor-targeted delivery, 325
radioreceptor assay, dopamine receptors, 283
radiotelemetry, intragastric pH measurement, 639
rat brain slices, incubation with substance P, 795
rat sandwich skin-flap model, 477
REC 15/2053 (flavone derivative), receptor binding studies, 430
receptor affinity for glucocorticoid-21 esters, 623
receptor binding studies, flavone and derivatives, 430
receptor targeting, magnetic chitosan microspheres, 300
receptor-avidin crosslinking, 790
receptor-mediated magnetic carriers, 300
recombinant DNA technology, 199
recombinant DNA, synthetic human insulin, 245
recombinant human interferon α-2a (rIFN α-2a), delivery to lymph, 472
rectal absorption enhancement, medium chain fatty acids, 453
red blood cells, adjuvant-membrane interaction model, 729
red blood cells, induced transition temperature and adjuvant effects, 729
reduced 3-suffix solubility equation, 193
reductive metabolism, xanthine oxidase-catalyzed anaerobic, 434
relaxants, skeletal muscle, 401
release profile, cumulative for microspheres, 178
release, from 2-phase emulsion type ointment, 16
renal drug transport, cimetidine, 465
methodology, 465
renal epithelia, transport processes, 465
renal failure, acute and furosemide response, 699
and di(2-ethylhexyl)phthalate, 10
renal metabolism of PAH, 745
renal transplantation in dogs, 781
renal transport of PAH, 745
renal transport, site identification techniques, 465
renal tubular secretion, phenylpropanolamine, 120
respiratory tract, drug dissolution or release, 574
righting reflex, loss of and skeletal muscle relaxants, 401

saliva analysis, endogenous hydrocortisone, 509
saturation level, of 2-phase emulsion type ointment, 16
secondary buffer, aliphatic carboxy ester of esmolol, 514
serotoninergic receptors, spasmolytic binding studies, 430
serum protein binding, aldose, reductase inhibitor, 261
diazepam, 261
in diabetes, 261
phenytoin, 261
propranolol, 261
shelf life prediction, injectable rAAT, 800
shelf life, prodrug approach, 288
prodrugs to improve, 634
size analysis, BCG vaccine, 607
Coulter and HIAC/Royco comparison, 607
skeletal muscle relaxants, loss of righting reflex, 401
skin flap, skin penetration of hydrocortisone, 477
skin hydration, NMR analysis, 611
skin irritation, relationship to pK_a, 660
skin penetration, hexamethylene lauramide, 477
transport kinetics, 753
skin permeation enhancers, indomethacin, 103
sodium ion excretion, and furosemide, 694
solid phase extraction from plasma, 365

solubility of nifedipine, enhancement via complexation, 655
solubility parameters, narcotic analgesics, 580
solubility, IDU prodrugs, 734
solubility, isoproterenol, 116
solubility, limit using potentiometric titration, 772
solubility, progabide, 226
solubilizing capacity of nonionic surfactants, 704
solute absorption from respiratory tract, 574
sparingly soluble drugs, ionization constants, 772
  limiting solubilities, 772
  potentiometric titration data, 772
spasmolytics, flavone and derivatives, 430
spasmolytics, receptor binding affinities, 430
spectinomycin, HPLC with electrochemical detection, 664
spectrophotometry, first and second order derivative, 709
squamous carcinoma cells, BUdR incorporation, 518
stability indicating assay, carmustine and lomustine, 220
  initial rate method, 249
stability, ampicillin, 288, 634
  bacampicillin, 288, 634
  isoproterenol, 116
  progabide, 226
  rAAT, 800
  secondary buffer system for degradation, 514
  talampicillin, 288, 634
stability-indicating assay, initial rate method, 250
  interpretation, 249
stationary disk/rotating fluid system, dissolution rate, 495
steady-state analysis, topical semisolid creams, 92
stereoisomers, binding to plasma proteins, 316
stereoselective binding, disopyramide, 316
stereospecific analysis, fenoprofen, 53
stratum corneum uptake mechanisms, 140
stratum corneum, lipid domains and solute uptake, 140
  permeability-partition coefficients, 566
  protein and lipid uptake, 566
  protein domains and solute uptake, 140
  uptake of hydrocortisone esters, 140
  water of hydration, 140
streptozotocin, effect on serum protein binding of drugs, 261
structural similarity and binding affinity, 408
sublingual administration, quazepam, 365
substance P binding technique, tritiated, 795
substance P receptor down-regulation, 795
sufentanil, solubility parameters, 580
sulfation, of acetaminophen, 61
superoxide dismutase, oxygen radical scavenging, 253
surfactant, effect on particle size distribution, 36
surfactants, fatty acid esters (Myrj), 704
  fatty alcohol ethers (Brij), 704
  nonionic, solubilizing capacity of, 704
  polyoxyethylen sorbitan monofatty acid esters, 704
synovial tissue, glucocorticoid receptors, 623
  receptor affinities, 623
systemic disposition, hexamethylene lauramide, 477

tablets, enteric coated, 550
talampicillin, bioavailability, 634
  prodrugs for improved shelflife, 288
targeted drug delivery, intrarenal infusion pump, 781
  lymphoid cells, 472
  recombinant human interferon, 472
  therapeutic radionuclides, 325
  to human neutrophils, 352
targeted drugs, chemotherapeutic agents, 539
targeting, biochemical and physical means, 300
  capillary endothelial cells, 300
  receptor-mediated magnetic carriers, 300
taste receptors and prodrugs, 615
taurodihydrofusidate, adjuvant effect on nasal absorption, 689
taurolithocholate, effect on metabolism of acetaminophen, 61
teratogenic anomalies, and ethanol, 447
terbutaline sulfate, metered dose powder inhaler, 506
terbutaline, as prodrug bambuterol, 151
testosterone esters, collision-activated dissociation mass spect., 31
  in imported oil injectables, 31
  structural determination in oil, 31
  thermospray, 31
theophylline, controlled release, 48
therapeutic drug monitoring, cyclosporin A, 80
thermal interactions of adjuvants on RBC membranes, 729
thermionic N-P specific detection with CG analysis, 220
thermodynamics, ephedrine diastereoisomers, 391
  solubility predictions of binary mixtures, 391
thermospray, 31
thymidine replacement kinetics in squamous carcinoma cells, 518
time-dependent kinetics, multiple dosing, 387
  phenprobamate, 387
timobesone acetate, micellar solubilization of, 704
  solubility, 704
tissue concentrations, 238
tolerance, acute of bumetanide, 86
topical dosage forms, transport, 377
topological approach, endogenous benzodiazepines, 408
  pharmacokinetics, 201
transdermal administration, indomethacin, 103
  of hydromorphone, pharmacokinetics, 718
transdermal delivery, isoproterenol, 116
  narcotic analgesics, 580
transdermal drug delivery, enhancement, 103
  indomethacin, 103
  iontophoretic diffusion cell, 443
transdermal penetration of diclofenac, 738
transdermal penetration, excised rat dorsal skin, 738
transepidermal water loss, 313
translation arrest, oligonucleotide analogues, 539
transport kinetics, skin penetration, 753
transport, cimetidine through choroid plexus, 628
transport, functional group contributions, 566
trobicin, degradation product of spectinomycin, 664
  HPLC with electrochemical detection, 664
tumor antigens, radiolabeled antibodies to, 325
tumor necrosis factor and inflammation, 129
Turbuhaler, low inspiratory flow rates, 506
  metered-dose powder inhaler, 506

ultrafiltration, phase distribution of prostaglandin E_1, 482
unbound plasma clearance, correlation between humans and rats, 668
unsteady-state analysis, topical semisolid creams, 92
uptake mechanisms, stratum corneum, 140
urease activity, effect of dry-state compactional pressure,776
urinary electrolytes in rats, 694
urinary excretion of furosemide, 699
urinary excretion, baclofen, 107
urinary pH modification, phenylpropanolamine disposition, 120
Ussing chamber, intestinal transport and metabolism, 598
utilization time, bacampicillin, 288
  computer simulation, 634
  talampicillin, 288

vaccine adjuvants, formulation, 523
ventriculocisternal perfusion, 628
volume fraction, internal phase of 2-phase emulsion ointment, 16

warfarin enantiomers, HPLC, 680
  serum levels, 680
water of hydration, stratum corneum, 140

X-ray diffractometry, cefazolin sodium, 426
xanthine oxidase-catalyzed anaerobic reduction, 434
xenobiotic molecules, metabolism and P450, 67

zoxazolamine, in CSF and serum, 401
  oxidative enzyme activity, 401
  pharmacodynamics, 401